970 results on '"Shelton, Richard C."'
Search Results
102. Presenting characteristics of depressed outpatients as a function of recurrence: Preliminary findings from the STAR*D clinical trial
103. Effort-Based Decision-Making in Major Depressive Disorder: A Translational Model of Motivational Anhedonia
104. Predictors of Patient Cognitive Therapy Skills and Symptom Change in Two Randomized Clinical Trials: The Role of Therapist Adherence and the Therapeutic Alliance
105. Depression in patients with head and neck cancer and a functional genetic polymorphism of the serotonin transporter gene
106. The Emperorʼs New Drugs: Effect Size and Moderation Effects
107. Response to: Goldberg et al. and Severance et al. Letters to the Editor: The clinical significance of improving remission over standard of care – The reality of treatment resistant-based therapies
108. Sustained amygdala response to both novel and newly familiar faces characterizes inhibited temperament
109. Effects of orally disintegrating vs regular olanzapine tablets on body weight, eating behavior, glycemic and lipid indices, and gastrointestinal hormones: A randomized, open comparison in outpatients with bipolar depression
110. Two Aspects of the Therapeutic Alliance: Differential Relations With Depressive Symptom Change
111. Adjunctive antidepressant treatment among 763 outpatients with bipolar disorder: Findings from the Bipolar CHOICE and LiTMUS trials
112. Improvement of sexual functioning during treatment of MDD with adjunctive pimavanserin: A secondary analysis
113. 150 HAM-D6 Outcomes in a Randomized, Controlled Trial Evaluating the Utility of Combinatorial Pharmacogenomics in Depression
114. COMBINATORIAL PHARMACOGENETIC TESTING IMPROVES RESPONSE AND REMISSION FOR PATIENTS OVER 65 WITH DEPRESSION WHO HAVE FAILED ONE MEDICATION TRIAL
115. 180 Improvement of Sexual Function Observed During Treatment of Major Depressive Disorder with Adjunctive Pimavanserin
116. 181 A Phase-2 Sequential Parallel Comparison Design Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder
117. Prevention of Recurrence After Recovery From a Major Depressive Episode With Antidepressant Medication Alone or in Combination With Cognitive Behavioral Therapy
118. Affective Science as a Framework for Understanding the Mechanisms and Effects of Antidepressant Medications.
119. Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder
120. Eating ourselves to death (and despair):: The contribution of adiposity and inflammation to depression
121. Ketamine for acute suicidal ideation. An emergency department intervention: A randomized, double‐blind, placebo‐controlled, proof‐of‐concept trial
122. Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled Trial
123. Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing
124. Efficacy, safety and tolerability of Symbyax® for acute-phase management of treatment-resistant depression
125. Olanzapine monotherapy for acute depression in patients with bipolar I or II disorder: results of an 8-week open label trial
126. Converting from brand-name to generic clozapine: A review of effectiveness and tolerability data
127. The Reliability and Validity of a Measure of Self-Understanding of Interpersonal Patterns
128. Obesogenic Medications and Weight Gain Over 24 Weeks in Patients with Depression: Results from the GUIDED Study.
129. Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder
130. Antidepressant medications v. cognitive therapy in people with depression with or without personality disorder
131. Olanzapine/fluoxetine combination for bipolar depression
132. Sequence variation in the human dopamine transporter gene in children with attention deficit hyperactivity disorder
133. Antidepressants.
134. Effects of a safe person on induced distress following a biological challenge in panic disorder with agoraphobia
135. Corrigendum to bipolar mixed features – Results from the comparative effectiveness for bipolar disorder (Bipolar CHOICE) study [Journal of Affective Disorders 217 (2017) 183–189]
136. Treating bipolar depression: newly diagnosed patients may resist taking a mood stabilizer, but the cycling--not just the depression--requires treatment. (Foundational treatment)
137. Fluoxetine and Olanzapine for Resistant Depression
138. Cognitive therapy for depression: conceptual issues and clinical efficacy
139. St John's Wort and Major Depression
140. Effectiveness of St John's Wort in Major Depression: A Randomized Controlled Trial
141. Serum Thyrotropin Concentrations and Bioactivity During Sleep Deprivation in Depression
142. A Novel Augmentation Strategy for Treating Resistant Major Depression
143. Contributors
144. Cognitive therapy and pharmacotherapy for depression
145. The Reliability and Validity of a Measure of Self-Understanding of Interpersonal Patterns
146. Major Depressive Disorder Following Dermatomyositis: A Case Linking Depression with Inflammation
147. A complex epigenetic switching is critical for TNF-α upregulation in prefrontal cortex of suicide subjects
148. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY)
149. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression
150. Effect of race on the relationship between child maltreatment and obesity in Whites and Blacks
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.